To our knowledge, this study is the first NMA that includes all cancers and provide important safety ranking of four treatment regimens involving ICI+ nab-PTX/PTX and a comparison of the safety profiles between PD-1 and PD-L1 inhibitors are provided as valuable references for clinical practice. Here, PDCD1 is linked to cancer.